Discover life science companies across the East of England, including biotechnology firms, CROs, research organisations and innovation hubs.
Preclinical RNA medicines for chronic liver disease and fibrosis
Afortiori Bio is a preclinical biotechnology company developing RNA medicines for chronic liver disease, particularly liver fibrosis. Its lead programme uses Target Site Blocker RNA technology to selectively modulate gene expression in liver cells. The approach is intended to address processes contributing to fibrotic…
Continuous industrial biocatalysis reactors and enzyme automation
Biozeroc is a Cambridge industrial biotechnology company developing continuous biocatalysis systems for large-scale manufacturing. Its technology combines enzyme immobilisation, reactor hardware and automation to maintain consistent output as enzyme activity declines, allowing industrial enzymes to operate for longer…
AI-driven intron technology to enhance transgene expression
ExpressionEdits is a biotechnology company developing computational tools to improve protein expression from artificial gene constructs. Its Genetic Syntax Engine uses machine learning and biological data to predict optimal intron insertion patterns within transgenes, increasing protein production levels in mammalian…
AI-driven neural data platform for bioelectronic medicine
BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation…
Benchtop platform for rapid cell-free protein expression and screening
Nuclera is a Cambridge-based biotechnology company developing benchtop systems for rapid protein expression and screening. Its discovery platform integrates cell-free protein synthesis, digital microfluidics, and automated construct screening to deliver soluble, active proteins in under 48 hours. The system is…
Lentiviral vector yield enhancement via HDAC inhibitors and producer lines
Synthistat is a biotechnology company developing technologies to increase lentiviral vector production for cell and gene therapy manufacturing. Its work combines designed histone deacetylase (HDAC) inhibitors with approaches to modify HEK293 producer cells. The company has reported early laboratory results from…
Small molecules improving ribosomal translation accuracy in ageing cells
Ribogenyx is a biotechnology company developing small-molecule therapies to improve protein synthesis accuracy in ageing cells. Its approach targets translational fidelity, the accuracy with which ribosomes translate messenger RNA into proteins. By reducing production errors, the company aims to preserve protein…
Gene editing platform for disease-resistant, climate-resilient tropical crops
Tropic Biosciences is an agricultural biotechnology company developing gene-edited varieties of tropical crops, including banana, coffee, and rice, with a focus on disease resistance, climate resilience, and yield improvement. Its proprietary platform combines gene editing with RNA interference to redirect a plant's…
Synthetic polymer affinity ligands for viral vector bioprocessing
Tozaro is a biotechnology company developing synthetic polymer-based affinity ligands to improve the downstream processing of viral vectors used in cell and gene therapy. Using molecular modelling and machine learning, Tozaro rationally designs polymer-based binders from a chemical space of over 500 monomers, offering…
Prospective human biosample collection for translational research
The Sample Network is a clinical research services company arranging human biosample collection for biomarker, diagnostic and therapeutic development. It works with a network of clinical sites to design prospective collection studies tailored to sample type, patient characteristics, processing protocols and associated…
Managed life science campus near Cambridge with flexible R&D space
Chesterford Research Park is a managed life sciences campus across 250 acres near Little Chesterford, Essex, within the Cambridge research cluster. The park provides flexible laboratory and office space for biotechnology, pharmaceutical and technology companies, with approximately 350,000 sq ft occupied and a…
Multivalent linker technologies for antibody-drug conjugate therapeutics
Spirea is a biopharmaceutical company developing antibody-drug conjugate technologies for targeted cancer treatment. Its multivalent linker platform is designed to attach a wider range of drug payloads to antibodies while enabling higher payload loading and controlled delivery. Spirea conducts preclinical research on…
Specialist CRO for ion channel screening and cardiac safety assessment
Metrion Biosciences is a contract research organisation specialising in preclinical ion channel biology, cardiac safety screening, and neuroscience drug discovery services. Founded in 2015 as a spin-out from Xention Limited, Metrion provides automated and manual patch clamp electrophysiology, GLP-compliant hERG…
In vivo nanoparticle screening for genetic medicine delivery
Ride Therapeutics is a joint University of Cambridge and Harvard spin-out developing nanoparticle delivery systems for mRNA and gene-editing medicines. Its Molecular Logistics platform engineers and screens large libraries of non-viral carriers in living systems, measuring tissue and cell-type targeting to train an…
TYK2/JAK1 inhibitor advancing towards Phase 2 psoriasis trials
Sareum is a clinical-stage biotechnology company developing small-molecule kinase inhibitors for autoimmune diseases and cancer. Its lead oral TYK2/JAK1 inhibitor, SDC-1801, completed Phase 1 testing in healthy volunteers and is being prepared for a Phase 2 study in psoriasis. Dosing in its Phase 2-enabling toxicology…
Coronary plaque biomarkers for precision cardiovascular medicine
PlaqueTec develops a catheter-based liquid biopsy system to investigate biological processes driving coronary artery disease. Its device samples blood at sites around coronary plaques, allowing researchers to compare local concentrations of proteins and other molecules. These data feed its BioCarta platform for…
Oral NLRP3 inhibitors for cardiovascular and neurologic inflammation
Rezera, formerly NodThera, is a clinical-stage biotechnology company developing small molecule inhibitors of NLRP3, an inflammasome implicated in chronic inflammatory and neurodegenerative disease. Its lead asset, ruvonoflast, is a brain-penetrant oral inhibitor that has completed Phase II trials and is advancing…
Integrated drug discovery CRO specialising in small molecule programmes
Domainex is a contract research organisation providing integrated drug discovery services to pharmaceutical companies, biotechnology firms, patient foundations and academic institutions. The company offers medicinal and computational chemistry, protein expression, assay development and structural biology, supporting…
Automated liquid handling and sample management instruments
SPT Labtech is a designer and manufacturer of laboratory automation instruments and consumables for liquid handling, sample preparation, and sample management. Its product portfolio includes nanolitre liquid handling systems for drug discovery and genomics workflows, cryo-electron microscopy sample preparation…
Research institute studying the biology of ageing and lifelong health
The Babraham Institute is a life sciences research institute studying the biological mechanisms behind ageing, development and lifelong health. Its research spans epigenetics, immunology and cellular signalling, investigating how gene activity, the immune system and intercellular communication shape health outcomes…